In June 2025, FDA launched the Commissioner’s National Priority Voucher (CNPV) pilot program, a new mechanism that promises eligible sponsors a decision on a new drug or biologic application in roughly one to two months, compared with the standard 10-12 month review clock. Unlike FDA’s two existing statutory Priority Review Voucher (PRV) programs, CNPV is not tied to a specific disease category defined by Congress — it is an agency pilot built around five broad “national priority” areas, and the vouchers it issues cannot be bought or sold. This page summarizes what CNPV is, how it differs from existing PRV programs, who has received a voucher so far, and where the program stands as FDA moves toward formalizing it through public comment in 2026.
What the CNPV Pilot Program Is
FDA announced the CNPV pilot program in June 2025 as a way to fast-track review of drug and biologic applications — including new drug applications (NDAs), biologics license applications (BLAs), and certain manufacturing or efficacy supplements — that align with a defined set of national priorities. Sponsors selected for a voucher get intensive, front-loaded engagement with FDA review staff (a “CNPV Review Council” and enhanced pre-submission engagement) in exchange for committing to a compressed, rolling-submission review timeline. FDA has framed the target review time as roughly one to two months from a complete application, a substantial reduction from the standard 10-12 month cycle for a standard NDA/BLA review.
Because CNPV was stood up as an FDA pilot program through agency announcement rather than new legislation, it operates on different footing than Priority Review Vouchers created by Congress. FDA has continued to develop the pilot’s operating details since the June 2025 launch, including through a 2026 public hearing and comment period discussed below.
Eligibility: The Five National Priority Areas
To be considered for a CNPV, FDA has said a sponsor’s product should align with at least one of five national priorities:
- Public health crisis response — products addressing an urgent or emerging public health threat, or with substantial population-level impact.
- Innovative, breakthrough therapies — treatments with a novel mechanism that meaningfully changes how a disease is managed.
- Addressing unmet medical needs — therapies for conditions where existing treatment options are inadequate.
- Onshoring / domestic manufacturing and supply-chain resilience — products where development or manufacturing is being onshored to the United States, reducing reliance on foreign supply chains.
- Improving affordability — approaches that lower overall cost to the healthcare system or otherwise improve access.
Interested sponsors submit a statement of interest to FDA through the agency’s CNPV submission process; selection is at FDA’s discretion rather than a formulaic eligibility test, and the agency has said it will award a limited number of vouchers per cycle.
How CNPV Differs From the Statutory Priority Review Voucher Programs
CASRAI’s Priority Review Voucher dictionary entry covers FDA’s two existing PRV programs: the Rare Pediatric Disease PRV program and the Tropical Disease PRV program, both created by acts of Congress amending the FD&C Act. CNPV is a distinct, newer mechanism, and the differences matter for anyone tracking regulatory strategy:
- Legal basis. The Rare Pediatric Disease and Tropical Disease PRV programs are statutory, created by Congress. CNPV is an FDA-initiated pilot program, launched by agency announcement rather than new legislation.
- Transferability. Rare Pediatric Disease and Tropical Disease PRVs can be sold or transferred to another sponsor — a market that has produced high-profile sales in the past. CNPV vouchers are nontransferable: they can only be used by the sponsor that was awarded them.
- Qualifying criteria. The statutory PRV programs are tied to a specific, narrow disease category (a designated rare pediatric disease, or a designated tropical disease). CNPV eligibility is framed around broader, more discretionary national-priority categories set by FDA rather than a fixed disease list.
- What the voucher buys. A traditional PRV entitles the holder to priority review (roughly six months) for a future, unrelated application. A CNPV is used on the qualifying application itself (or a related supplement) and promises a much shorter, roughly one-to-two-month review.
In short: both are FDA incentive mechanisms tied to the review clock, but CNPV is newer, agency-created rather than statutory, non-transferable, and aimed at a different, broader set of policy goals than the two disease-specific PRV programs.
Program Status: Vouchers Awarded So Far
FDA named its first CNPV recipients on October 16, 2025 — nine products, according to FDA’s announcement. A second batch followed on November 6, 2025, adding six more products; coverage of that announcement identified the additional products as including therapies for HER2-positive lung cancer, drug-resistant tuberculosis, rectal cancer, sickle cell disease, and two GLP-1 obesity therapies. Combined, that put the total at 15 vouchers awarded across the program’s first two rounds.
FDA’s own March 2026 Federal Register notice announcing a public hearing on the pilot reported further progress since those first two rounds, citing vouchers awarded for 18 products in total and describing four approvals reached under the program, including two oncology approvals reported at 44 and 55 days from filing — well inside the program’s one-to-two-month target and far faster than a standard review cycle. Readers should treat the exact running total as a snapshot rather than a fixed number: FDA has continued to make new CNPV awards, and the agency’s own postings are the authoritative source for the current count.
FDA’s 2026 Public Hearing and Comment Period
In March 2026, FDA published a Federal Register notice announcing a public hearing and formal request for comments on the CNPV pilot program, later amended to reschedule the hearing date. The stated agenda covered the pilot’s scope and the five national priority areas, the voucher selection process, enhanced regulatory engagement and pre-submission/rolling-submission requirements, the CNPV timeline, the CNPV Review Council, sponsor responsibilities, and program evaluation going forward. The hearing was held at FDA’s White Oak campus, with a written comment period running through late June 2026. This process signals FDA is actively refining and evaluating the pilot rather than treating its initial 2025 parameters as final — worth watching for anyone advising sponsors on regulatory strategy or tracking how the program may evolve past its pilot phase.
Open Questions and Implementation Concerns
Health-policy analysts have raised several open questions about CNPV as it scales beyond its first year:
- The program’s core incentive — a faster review clock — is a drug-approval lever, which some analysts argue is a mismatch for non-clinical national priorities like onshoring manufacturing or improving affordability; a faster FDA review does not, by itself, guarantee a company follows through on a manufacturing or pricing commitment.
- Because CNPV vouchers are nontransferable, they cannot be used the way statutory PRVs sometimes are — as an incentive a smaller developer can sell to fund further R&D, or as a lever for a generic manufacturer to invest in domestic capacity.
- Compressing review timelines to one to two months raises resourcing questions for FDA review divisions, including whether the fastest CNPV reviews come at the cost of delaying other, non-CNPV applications in the queue.
- Because many CNPV commitments (e.g., onshoring or affordability pledges) are not independently verified conditions of approval in the way a clinical endpoint is, several commentators have noted the program currently lacks binding mechanisms to confirm non-clinical commitments are actually delivered after a voucher is used.
FDA’s 2026 public hearing and comment process is, in part, a response to these open questions — it is reasonable to expect the pilot’s operating rules to be refined based on that input.
What This Means for Research Administrators and Sponsors
For institutions and companies tracking FDA regulatory strategy, CNPV is a relevant addition to the existing expedited-pathway toolkit alongside Priority Review, Breakthrough Therapy designation, Accelerated Approval, and Fast Track — CASRAI’s FDA expedited programs guide compares those four established pathways in detail. CNPV is a separate, additional mechanism layered on top of that existing framework rather than a replacement for it, and because selection is discretionary and the program is still being formalized through FDA’s 2026 rulemaking-adjacent hearing process, sponsors evaluating whether a candidate product might fit one of the five national priority areas should treat FDA’s own CNPV program page and Federal Register postings as the definitive, current source before making submission decisions.
Frequently Asked Questions
What is the FDA Commissioner’s National Priority Voucher (CNPV)?
It is an FDA pilot program, launched in June 2025, that awards selected sponsors an expedited review — roughly one to two months — for a drug or biologic application that aligns with one of five FDA-defined national priorities.
Is a CNPV voucher transferable or sellable, like a Priority Review Voucher?
No. Unlike the statutory Rare Pediatric Disease and Tropical Disease Priority Review Vouchers, which can be sold or transferred to another sponsor, CNPV vouchers are nontransferable and can only be used by the sponsor FDA awarded them to.
How many CNPV vouchers has FDA awarded?
FDA awarded its first nine CNPV vouchers on October 16, 2025, and six more on November 6, 2025, for a total of 15 in the program’s first two rounds. FDA’s March 2026 Federal Register notice cited 18 products awarded vouchers by that point, with four approvals reached under the program. Because FDA continues to make new awards, check FDA’s own CNPV program page for the current running total.
How is CNPV different from the existing Priority Review Voucher programs?
The existing Rare Pediatric Disease and Tropical Disease PRV programs are created by statute, tied to a specific disease category, and transferable/sellable. CNPV is an FDA pilot program (not created by new legislation), tied to five broader national-priority categories rather than one disease area, and its vouchers cannot be sold or transferred.
How does a company apply for a CNPV?
FDA has directed interested sponsors to submit a statement of interest through the agency’s CNPV Pilot Program submission process; selection is discretionary and FDA has indicated it will award a limited number of vouchers per award cycle.
